NASDAQ:XNCR

Xencor Q1 2025 Earnings Results & Report

Xencor logo
$34.50 -0.90 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$34.49 -0.01 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xencor missed analyst earnings expectations but beat on revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.66 versus the -$0.60 consensus estimate, while revenue of $32.73 million topped the $23.44 million estimate by $9.29 million. Revenue increased 104.6% year over year.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

Xencor EPS Results

Actual EPS
-$0.66
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.06
One Year Ago EPS
-$1.11
EPS Beat Rate
6 of last 8 quarters

Xencor Revenue Results

Actual Revenue
$32.73 million
Expected Revenue
$23.44 million
Beat/Miss
Beat by +$9.29 million
YoY Revenue Growth
+104.60%

Xencor Q1 2025 Earnings FAQ

Xencor (NASDAQ:XNCR) reported earnings of -$0.66 per share for Q1 2025, missing the consensus estimate of -$0.60. The report was announced on Thursday, May 8, 2025.

Xencor reported revenue of $32.73 million for Q1 2025, against a consensus estimate of $23.44 million.

Xencor Earnings Headlines

Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
Xencor (NASDAQ:XNCR) Stock Rating Raised to "Buy" at Wall Street Zen
See More Xencor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email.

About Xencor

Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target.

Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets. The company is headquartered in Monrovia, California, and its collaborations extend its work with partners beyond the United States.

Founded in 1997, Xencor is led by co-founder and Chief Executive Officer Bassil I. Dahiyat, Ph.D. Its focus is on developing and partnering antibody medicines rather than operating as a broad commercial drug manufacturer.

View Xencor Profile